Swapping Stories: Gaining insight to cancer therapeutics and EGFR signaling from flies Public
Downloadable Contentopen in viewer
Breast cancer affects ~1 million new women yearly. Overexpression of ErbB2, a member of the EGFR family, is a causative factor in 30% of these cases and is targeted by the cancer drug Herceptin. Strikingly, studies of ErbB2 and the Drosophila EGFR have uncovered a close structural relationship. Using domain swaps between dEGFR and ErbB2, I have been investigating inhibition of dEGFR by the transmembrane molecule Kekkon1 with the hope that such insight may lead to novel cancer drugs.
- This report represents the work of one or more WPI undergraduate students submitted to the faculty as evidence of completion of a degree requirement. WPI routinely publishes these reports on its website without editorial or peer review.
- Date created
- Resource type
- Rights statement
Permanent link to this page: https://digital.wpi.edu/show/zs25x9726